A RANDOMIZED, DOUBLE-BLIND TRIAL OF ABATACEPT (CTLA4-IG) FOR THE TREATMENT OF GIANT CELL ARTERITIS

OBJECTIVE: To compare the efficacy of abatacept to placebo for giant cell arteritis (GCA). METHODS: In this multicenter trial, patients with newly-diagnosed or relapsing GCA were treated with abatacept 10 mg/kg IV on days 1, 15, 29, week 8, together with prednisone. At week 12, patients in remission...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Rheumatol
Main Authors: Langford, Carol A., Cuthbertson, David, Ytterberg, Steven R., Khalidi, Nader, Monach, Paul A., Carette, Simon, Seo, Philip, Moreland, Larry W., Weisman, Michael, Koening, Curry L, Sreih, Antoine, Spiera, Robert, McAlear, Carol A., Warrington, Kenneth J., Pagnoux, Christian, McKinnon, Kathleen, Forbess, Lindsy J., Hoffman, Gary S., Borchin, Renée, Krischer, Jeffrey P., Merkel, Peter A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2017
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5378642/
https://ncbi.nlm.nih.gov/pubmed/28133925
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40044
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados